# dimension.bio > AI-optimized mirror of dimension.bio containing 21 pages totalling 8,256 words of clean markdown content, structured data, and semantic HTML. Original source: https://dimension.bio/. Last updated: 2026-04-25T19:28:41.332Z. Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG). ## Homepage - [site-root.html](/site-root.html) (1 words) ## Articles & Blog Posts - [Dimension Bio](/cart/index.html) (1 words) - [home/index.html](/home/index.html) (1 words) - [Press Release](/pr-2025-advisory-board-announcement/index.html): Dimension Bio announced the formation of its inaugural Clinical and Scientific Advisory Boards, uniting global experts in hepatology, organ transplantation, and biomaterials engineering. The boards will guide the company’s BioNidum™ tissue therapeutics program as it advances from strong preclinical , Dimension Bio announced the formation of its inaugural Clinical and Scientific Advisory Boards, uniting global experts in hepatology, organ transplantation, and biomaterials engineering. The boards will guide the company’s BioNidum™ tissue therapeutics program as it advances from strong preclinical results toward first-in-human studies for liver failure. (1,160 words) - [Press Release](/pr-series-a/index.html): Dimension Inx Raises $12M Series A to Accelerate Commercialization of New Generation of Regenerative Therapeutics, Dimension Inx Raises $12M Series A to Accelerate Commercialization of New Generation of Regenerative Therapeutics (643 words) - [Press Release](/pr-2025-aasld-presentation-new-preclinical-results/index.html): Dimension Bio presented new preclinical data at AASLD 2025 showing that its BioNidum™ 3D-printed implant enables long-term hepatocyte survival, vascularization, and improved survival in liver failure models. The results support BioNidum™ as a minimally invasive, cell-based therapy designed to restor, Dimension Bio presented new preclinical data at AASLD 2025 showing that its BioNidum™ 3D-printed implant enables long-term hepatocyte survival, vascularization, and improved survival in liver failure models. The results support BioNidum™ as a minimally invasive, cell-based therapy designed to restore liver function and outperform hydrogel-based systems. (381 words) - [Press Release](/pr-cmflex/index.html): Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor, Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor (692 words) - [Press Release](/pr-2025-ascgt-presentation/index.html): Dimension Bio to Present New Preclinical Data on BioNidum™ Therapeutic Cell Delivery System at the 2025 American Society of Gene & Cell Therapy Meeting, Dimension Bio to Present New Preclinical Data on BioNidum™ Therapeutic Cell Delivery System at the 2025 American Society of Gene & Cell Therapy Meeting (439 words) - [Press Release](/pr-2025-nasdaq-chicago-innovation/index.html): Dimension Bio, a biotechnology company pioneering regenerative therapeutics, joined fellow winners of the Chicago Innovation Awards, the Chicago region’s foremost annual celebration of innovation, in New York City on Friday, August 1st to ring the Closing Bell of the Nasdaq Stock Market., Dimension Bio, a biotechnology company pioneering regenerative therapeutics, joined fellow winners of the Chicago Innovation Awards, the Chicago region’s foremost annual celebration of innovation, in New York City on Friday, August 1st to ring the Closing Bell of the Nasdaq Stock Market. (516 words) - [Press Release](/pr-2024-chicago-innovation-awards/index.html): Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor, Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor (462 words) - [Press Release](/pr-2025-pml-podcast-breakthrough-tissue-therapeutics.html): Dimension Bio CEO Caralynn Nowinski Collens is featured on the Prime Movers Lab Podcast, sharing the company’s mission to develop regenerative tissue therapeutics. She highlights BioNidum™, their cell-based platform addressing acute liver failure, her path from physician to entrepreneur, and how Dim, Dimension Bio CEO Caralynn Nowinski Collens is featured on the Prime Movers Lab Podcast, sharing the company’s mission to develop regenerative tissue therapeutics. She highlights BioNidum™, their cell-based platform addressing acute liver failure, her path from physician to entrepreneur, and how Dimension Bio is advancing differentiated therapies in a high-need and growing market. (377 words) - [Press Release](/pr-2025-regen-valley-techhub-awards/index.html): Dimension Bio Secures Commercialization Resource Awards from ReGen Valley Tech Hub - Support includes strategic regulatory, manufacturing, and reimbursement services to accelerate their BioNidum™-empowered cell therapies, Dimension Bio Secures Commercialization Resource Awards from ReGen Valley Tech Hub - Support includes strategic regulatory, manufacturing, and reimbursement services to accelerate their BioNidum™-empowered cell therapies (481 words) - [Press Release](/pr-fundraising/index.html) (502 words) - [Press Release](/pr-2025-heidi-hagen-board/index.html): Dimension Bio appoints biotechnology veteran Heidi Hagen to its Board of Directors, bringing decades of cell therapy leadership as the company advances its liver failure program toward the clinic., Dimension Bio appoints biotechnology veteran Heidi Hagen to its Board of Directors, bringing decades of cell therapy leadership as the company advances its liver failure program toward the clinic. (493 words) - [Press Release](/pr-2024-innovationbydesign/index.html): Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor, Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor (465 words) - [Company Announcement](/announcement-patent-fluffy-and-tissuepaper/index.html): Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor, Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor (320 words) - [**Introducing Dimension Bio**](/introducing-dimension-bio/index.html): With over 20 years of experience in biomaterials and tissue engineering, she has established herself as a renowned leader in materials development for 3D- ..., With over 20 years of experience in biomaterials and tissue engineering, she has established herself as a renowned leader in materials development for 3D- ... (277 words) - [Press Release](/pr-grantaward/index.html) (571 words) - [Company Announcement](/announcement-patent-selfgelling/index.html): Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor, Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor (346 words) - [Be a part of a team that is actively innovating and changing the way we treat patients.](/careers/index.html) (117 words) - [That page doesn’t exist.](/404/index.html) (11 words) ## Resources - [Full Page Index](/index.html): Browse all cached pages with rich metadata - [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines - [XML Sitemap](/content/sitemap.xml): Machine-readable sitemap for crawler discovery - [Robots.txt](/content/robots.txt): Crawler directives